Trial · NCT01832870
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
NCT01832870, Phase 1, Completed, Prostate Oncology Specialists, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer. Trials, record NCT01832870. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01832870
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
- NCT number
- NCT01832870
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 9 participants, actual
- Lead sponsor
- Prostate Oncology Specialists, Inc.
- Conditions
- Prostate Cancer, Castrate Resistant Prostate Cancer
- Interventions
- sipuleucel-T, ipilimumab
- First posted
- 2013-04-16
- Last updated
- 2017-08-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Antigen-specific memory T cell response | After last sipuleucel-T and last ipilimumab, and follow-up period, an expected average of 15 months | To quantify antigen-specific memory T cell response to sipuleucel-T and ipilimumab in combination. |
| Primary | Antigen-specific T cell proliferation to PA2024, PAP and PHA | After last sipuleucel-T and last ipilimumab, and follow-up period, an expected average of 15 months | To quantify Antigen-specific T cell proliferation to PA2024, PAP and PHA when sipuleucel-T and ipilimumab are given in combination. * PA2024 is a recombinant protein * PAP: Prostatic acid phosphatase * PHA: Phytohaemagglutinin, an assay control |
| Primary | Antibody responses against PA2024 and PAP | After last sipuleucel-T and last ipilimumab, and the follow-up period, an expected average of 15 months | To quantify antibody responses against PA2024 and PAP. * PA2024 is a recombinant protein * PAP: Prostatic acid phosphatase |
| Secondary | Prostate-Specific Antigen (PSA) doubling time | Duration of the study, an expected average of 18 months | To measure changes in PSA doubling time following treatment with sipuleucel-T and ipilimumab |
| Secondary | Time to PSA progression | Duration of the study, an expected average of 18 months | To quantify time to PSA progression after treatment with sipuleucel-T and ipilimumab |
| Secondary | Time to salvage therapy | Duration of the study, an expected average of 18 months | To quantify time to salvage therapy after treatment with sipuleucel-T and ipilimumab |
| Secondary | Percentage PSA decline | Duration of the study, an expected average of 18 months | To measure percentage PSA decline following treatment with sipuleucel-T and ipilimumab |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01832870
GET https://conductscience.org/api/trials/v1/NCT01832870/registered